Earnings
Vir Biotechnology Trims Quarterly Loss To $96.3 Million As Hepatitis Delta Readout Nears
Vir expects topline data from its pivotal ECLIPSE 1 trial in the fourth quarter, and says its cash lasts into the second half of 2028.
VIR
Vir Biotechnology (VIR) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Vir CEO Says Hepatitis Delta Combo Could Be 'Best-In-Class' As Rival's Phase 3 Data Land
The first of three late-stage readouts is due this quarter, and the company says its Phase 2 showed undetectable virus in 66% of patients.
Earnings
Vir Biotechnology Books Negative Revenue Of $188,000 As Partners Cover More Of Its Trial Bills
Partner cost recoveries cut Vir's third-quarter R&D to $80.0 million while cash fell to about $901.3 million before a $90.0 million Gilead payment.
SEC Filings
Vir Biotechnology Adds Cancer Immunotherapy Researcher Suzanne Topalian As Ninth Director
Vir's board grows from eight to nine members, and Topalian also joins the Science and Technology Committee.
SEC Filings
Vir Biotechnology Could Collect Up To $135 Million Near Term From Gilead Cancer Deal
Gilead gets an exclusive license to three solid-tumor T-cell engagers and will buy about $25 million of Vir stock; $1.74 billion more is possible.
SEC Filings
Vir's Prostate Cancer Drug VIR-5500 Gets FDA Fast Track Status, With Phase 3 Planned For 2027
The designation covers late-line metastatic castration-resistant prostate cancer; Vir and Astellas co-develop the drug.